Illumina, Inc. (ILMN)
Illumina Transaction Conference Call
January 25, 2012 7:00 am ET
Daniel O'Day - Chief Executive Officer of Roche Molecular Diagnostics and President of Roche Molecular Diagnostics
Severin Schwan - Chief Executive officer
Alan Hippe - Chief Financial and IT Officer
Vincent Meunier - Exane BNP Paribas, Research Division
Gbola Amusa - UBS Investment Bank, Research Division
Keyur Parekh - Goldman Sachs Group Inc., Research Division
Luisa Hector - Crédit Suisse AG, Research Division
Sachin Jain - BofA Merrill Lynch, Research Division
Alexandra Hauber - JP Morgan Chase & Co, Research Division
Quintin J. Lai - Robert W. Baird & Co. Incorporated, Research Division
Michael Leacock - RBS Research
William R. Quirk - Piper Jaffray Companies, Research Division
Previous Statements by ILMN
» Illumina's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Illumina's CEO Discusses Q2 2011 Results - Earnings Call Transcript
» Illumina's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Welcome to everybody, and thank you for joining our call, which is going to last for about one hour. This is Severin speaking, and with me today, Alan Hippe, our Chief Financial Officer; and Dan O'Day, Chief Operating Officer of Roche Diagnostics.
Illumina is a great successful company, and we are excited to share with you the background of this planned acquisition. At the beginning, just let me shortly put this transaction into context. An important element of today's success of Roche Diagnostics is our breadth and depth of various key measuring technologies. They allow us to develop and market a broad range of diagnostic tests from molecular diagnostics to serum work area or tissue diagnostic testing. The completeness of our offering is important, both for our customers and Roche.
Over the years, we have developed a number of high-tech platforms, both internally and also as you can see on Page 4, by acquiring a number of key technologies. And we believe that sequencing is and will continue to be an increasingly important technology as we go forward.
Let me focus on 3 points specifically: first, it will allow us to further strengthen our clear #1 position as the leader in the worldwide diagnostics market. The depth and breadth of our offering to our customers will continue to be a key differentiator in the marketplace. Second, Roche's strong global footprint and expertise in the research and diagnostics market would certainly help to accelerate the transition of sequencing into research and clinical diagnostics around the world. And third, with a wide range of technologies available within the Roche Group, we will also be able to strengthen our in-house collaboration between pharma and diagnostics in our efforts to develop more targeted medicines.
So combining the strengths and capabilities of Roche and Illumina makes a lot of sense, both from a strategic and an operational point of view. We firmly believe that we will create value for both companies, and this is why we approached Illumina back in December last year.
Unfortunately, the board of Illumina has not been interested to negotiate a business combination, and for this reason, we are now directly approaching Illumina's shareholders and offer a price per share of USD $44.5. This represents an overall consideration of USD $5.7 billion. We believe this is a compelling offer, and we feel that Illumina's shareholders will find it extremely attractive. It certainly represents full and fair value of Illumina.
As I said at the beginning, Illumina is a great and successful company. Together with the management and employees of Illumina, we want to bring our combined business to the next level.
With this, I hand over to Dan.
So thank you, everybody. Good afternoon, good morning, this is Dan O'Day speaking. And it's a great pleasure today for me to walk you through the transaction rationale. Now let me just start by expressing also my enthusiasm for this acquisition and the value that I'm convinced it will create for both shareholders of both organizations and also for the employees involved.
Now what I'd like to do is really walk you through why. Why is that the case? What is the acquisition rationale? And importantly, why now? And I hope that I get through all those points during my talk. In order to set up what the combined entities can bring together from a synergy perspective, let me first just remind you what we're talking about in terms of the 2 separate entities and what they bring to the table.
So referring to Slide 6 just to set the scene, Roche Diagnostics is by far the #1 company in-vitro diagnostics. It is growing consistently ahead of the market, has been for the past 5 years. And part of what allows us to continue to grow ahead of the market like that is this broad array of technologies, the ability to bring solutions to labs and to patients around the world regardless of where the science leads is an extremely important aspect to our business.
And in that regard, the other aspect is the very large commercial presence that we have around the world. We are present in more than 130 countries. We have literally hundreds of thousands of instruments. We have sales people and service people in every corner of the world that allow us to leverage these technologies to the benefit of our customers.
Turning to Slide 7 gives you an overview of what other businesses we're in today. And importantly, what I want to point out here today is that many of our businesses are in the in-vitro diagnostics settings. And just to clarify that, that really means that is the clinical setting. That's where labs are providing data output and solution output to clinicians that make decisions on patients. This is the regulated portion of our business. It implies that you have to have a very high quality level, high validation level and reproducibility throughout the world. Then you can see we have a variety of businesses in that segment. We also have an active business, an important business to our strategy in the Life Sciences, which calls on a different customer base today. It calls upon the research audience.